Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL

European Journal of Cancer

Volumn 46, Issue 10, 2010, Pages 1848-1855

  Vallance, Kelly ^a   Liu, Wei ^b   Mandrell, Belinda N ^b   Panetta, John C ^b   Gattuso, Jami S ^b   Hockenberry, Marilyn ^c   Zupanec, Sue ^d   Yang, Lei ^b   Yang, Jie ^b   Hinds, Pamela S ^e  

^a Cook Children's Medical Center ^*  (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c TEXAS CHILDREN S CANCER CENTER   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Dexamethasone; Fatigue; Paediatric acute lymphoblastic leukaemia; Pharmacogenomics; Pharmacokinetics; Single nucleotide polymorphism (SNP); Sleep

Indexed keywords

DEXAMETHASONE; FETUIN A; INTERLEUKIN 6; SERUM ALBUMIN; TRIAMCINOLONE ACETONIDE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ACTIMETRY; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER RISK; CHILD; CHILDHOOD CANCER; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; FATIGUE; FEMALE; GENE LOCUS; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PEDIATRICS; PHARMACOGENETICS; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; SCHOOL CHILD; SLEEP DISORDER; SLEEP PATTERN; CHEMICALLY INDUCED; CLINICAL TRIAL; GENETICS; METABOLISM; MULTICENTER STUDY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ANTINEOPLASTIC AGENTS, HORMONAL; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; FATIGUE; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTORS; SERUM ALBUMIN; SLEEP DISORDERS;

EID: 77953293824     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.03.026     Document Type: Article

References (45)

1. Pui C.H., and Evans W.E. Treatment of acute lymphoblastic leukemia. N Engl J Med 354 2 (2006) 166-178
2. Gaynon P.S., Trigg M.E., Heerema N.A., et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 14 12 (2000) 2223-2233
3. Veerman A.J., Hahlen K., Kamps W.A., et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 14 3 (1996) 911-918
4. Balis F.M., Lester C.M., Chrousos G.P., Heideman R.L., and Poplack D.G. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J Clin Oncol 5 2 (1987) 202-207
5. Jones B., Freeman A.I., Shuster J.J., et al. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 19 4 (1991) 269-275
6. Czock D., Keller F., Rasche F.M., and Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44 1 (2005) 61-98
7. Richter O., Ern B., Reinhardt D., and Becker B. Pharmacokinetics of dexamethasone in children. Pediatr Pharmacol (New York) 3 3-4 (1983) 329-337
8. Yang L., Panetta J.C., Cai X., et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 26 12 (2008) 1932-1939
9. Drigan R., Spirito A., and Gelber R.D. Behavioral effects of corticosteroids in children with acute lymphoblastic leukemia. Med Pediatr Oncol 20 1 (1992) 13-21
10. Hinds P.S., Hockenberry M.J., Gattuso J.S., et al. Dexamethasone alters sleep and fatigue in pediatric patients with acute lymphoblastic leukemia. Cancer 110 10 (2007) 2321-2330
11. Stuart F.A., Segal T.Y., and Keady S. Adverse psychological effects of corticosteroids in children and adolescents. Arch Dis Child 90 5 (2005) 500-506
12. Adam K., and Oswald I. Protein synthesis, bodily renewal and the sleep-wake cycle. Clin Sci (Lond) 65 6 (1983) 561-567
13. Akerstedt T., Palmblad J., de la T.B., Marana R., and Gillberg M. Adrenocortical and gonadal steroids during sleep deprivation. Sleep 3 1 (1980) 23-30
14. Mindell J.A., and Owens J.A. A clinical guide to pediatric sleep: diagnosis and management of sleep problems (2003), Williams & Wilkins Publishers, Philadelphia, PA, Lippincott
15. Hart C.N., Palermo T.M., and Rosen C.L. Health-related quality of life among children presenting to a pediatric sleep disorders clinic. Behav Sleep Med 3 1 (2005) 4-17
16. Sadeh A., Gruber R., and Raviv A. Sleep, neurobehavioral functioning, and behavior problems in school-age children. Child Dev 73 2 (2002) 405-417
17. Meeske K.A., Siegel S.E., Globe D.R., Mack W.J., and Bernstein L. Prevalence and correlates of fatigue in long-term survivors of childhood leukemia. J Clin Oncol 23 24 (2005) 5501-5510
18. Mindell J.A., Owens J.A., and Carskadon M.A. Developmental features of sleep. Child Adolesc Psychiatr Clin N Am 8 4 (1999) 695-725
19. Meltzer L.J., and Mindell J.A. Sleep and sleep disorders in children and adolescents. Psychiatr Clin North Am 29 4 (2006) 1059-1076
20. Sadeh A., Hauri P.J., Kripke D.F., and Lavie P. The role of actigraphy in the evaluation of sleep disorders. Sleep 18 4 (1995) 288-302
21. Sanford S.D., Okuma J.O., Pan J., et al. Gender differences in sleep, fatigue, and daytime activity in a pediatric oncology sample receiving dexamethasone. J Pediatr Psychol 33 3 (2008) 298-306
22. Shafqat A., Einhorn L.H., Hanna N., et al. Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment. Ann Oncol 16 9 (2005) 1545-1550
23. Wang X.S., Giralt S.A., Mendoza T.R., et al. Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma. J Clin Oncol 20 5 (2002) 1319-1328
24. Wratten C., Kilmurray J., Nash S., et al. Fatigue during breast radiotherapy and its relationship to biological factors. Int J Radiat Oncol Biol Phys 59 1 (2004) 160-167
25. Relling M.V., Yang W., Das S., et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 22 19 (2004) 3930-3936
26. Evans W.E., and Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286 5439 (1999) 487-491
27. Ueda K., Yoshida A., and Amachi T. Recent progress in P-glycoprotein research. Anticancer Drug Des 14 2 (1999) 115-121
28. Huizenga N.A., Koper J.W., De Lange P., et al. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 83 1 (1998) 144-151
29. Hinds P.S., Hockenberry-Eaton M., Gilger E., et al. Comparing patient, parent, and staff descriptions of fatigue in pediatric oncology patients. Cancer Nurs 22 4 (1999) 277-288
30. Hinds P.S., Quargnenti A., Bush A.J., et al. An evaluation of the impact of a self-care coping intervention on psychological and clinical outcomes in adolescents with newly diagnosed cancer. Eur J Oncol Nurs 4 1 (2000) 6-17
31. D'Argenio D., and Schumitzky A. ADAPT II user's guide (2008), Biomedical Simulations Resource, USC, Los Angeles
32. Osawa M., Umetsu K., Ohki T., Nagasawa T., Suzuki T., and Takeichi S. Molecular evidence for human alpha 2-HS glycoprotein (AHSG) polymorphism. Hum Genet 99 1 (1997) 18-21
33. Inoue M., Takata H., Ikeda Y., et al. A promoter polymorphism of the alpha2-HS glycoprotein gene is associated with its transcriptional activity. Diabetes Res Clin Pract 79 1 (2008) 164-170
34. Francke S., Manraj M., Lacquemant C., et al. A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27. Hum Mol Genet 10 24 (2001) 2751-2765
35. Kissebah A.H., Sonnenberg G.E., Myklebust J., et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA 97 26 (2000) 14478-14483
36. Vionnet N., Hani E.H., Dupont S., et al. Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet 67 6 (2000) 1470-1480
37. Siddiq A., Lepretre F., Hercberg S., Froguel P., and Gibson F. A synonymous coding polymorphism in the alpha2-Heremans-schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians. Diabetes 54 8 (2005) 2477-2481
38. Stefan N., Hennige A.M., Staiger H., et al. Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 29 4 (2006) 853-857
39. Woltje M., Tschoke B., von B V., et al. CCAAT enhancer binding protein beta and hepatocyte nuclear factor 3beta are necessary and sufficient to mediate dexamethasone-induced up-regulation of alpha2HS-glycoprotein/fetuin-A gene expression. J Mol Endocrinol 36 2 (2006) 261-277
40. Lee B.N., Dantzer R., Langley K.E., et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation 11 5 (2004) 279-292
41. Wood L.J., Nail L.M., Gilster A., Winters K.A., and Elsea C.R. Cancer chemotherapy-related symptoms: evidence to suggest a role for proinflammatory cytokines. Oncol Nurs Forum 33 3 (2006) 535-542
42. Vgontzas A.N., Bixler E.O., Lin H.M., Prolo P., Trakada G., and Chrousos G.P. IL-6 and its circadian secretion in humans. Neuroimmunomodulation 12 3 (2005) 131-140
43. Belluco C., Olivieri F., Bonafe M., et al. 174 G>C polymorphism of interleukin 6 gene promoter affects interleukin 6 serum level in patients with colorectal cancer. Clin Cancer Res 9 6 (2003) 2173-2176
44. Hoffmann S.C., Stanley E.M., Darrin C.E., et al. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation 72 8 (2001) 1444-1450
45. Avila J., Acosta E., Machargo M.D., et al. Autoantigenic nuclear proteins of a clinically atypical renal vasculitis. J Autoimmune Dis 5 (2008) 3